The study, recently published in Acta Neuropathologica Communications, goes beyond previous understandings of autophagy in ALS by focusing specifically on CMA, a selective mechanism by which cells degrade aberrant or damaged proteins. Unlike macroautophagy, which broadly targets cellular debris, CMA identifies and degrades specific protein cargos, a function essential to maintaining neuronal homeostasis. In ALS, where toxic aggregates of the RNA-binding protein TDP-43 accumulate abnormally in motor neurons, the failure of such precision clearance mechanisms could be a driver of cellular degeneration.

To delve into these molecular intricacies, researchers obtained post-mortem spinal cord tissues from ALS patients enrolled in clinical trials and from age-matched healthy donors. Employing advanced immunohistochemistry and immunofluorescence techniques, they quantified levels of LAMP2A, a lysosomal membrane receptor pivotal for substrate translocation in CMA. Strikingly, motor neurons from ALS patients exhibited a pronounced reduction in LAMP2A expression and activity compared to controls, pointing to a compromised CMA pathway as a consistent hallmark in the diseased state.

ALS predominantly affects motor neurons, specialized nerve cells responsible for initiating muscle contractions. In the majority of ALS cases, these neurons harbor cytoplasmic aggregates of TDP-43, a protein normally residing in the nucleus and involved in RNA metabolism. The aberrant cytoplasmic localization of TDP-43 is toxic, disrupting cellular function and viability. The researchers propose that a decline in CMA preferentially impairs the degradation of such proteins, facilitating their pathological accumulation. This observation challenges prior assumptions that generalized autophagy declines were solely responsible, highlighting CMA’s unique and indispensable role.

Professor Salvador Martínez, the laboratory director overseeing this research, emphasized that restoring CMA function may be pivotal for motor neuron survival. “Motor neurons require exceptionally high CMA activity to maintain proteostasis. When this system falters, as observed in ALS, these neurons become especially vulnerable, leading to the progressive neurodegeneration characteristic of the disease,” he explained. This insight underscores the therapeutic potential of pharmacologically or genetically modulating CMA to augment its protein-clearance capacity.

One of the most compelling aspects of this investigation is the direct demonstration of CMA dysfunction in human neuronal tissue, a feat rarely achievable in animal models. This human-centric approach affirms the biological relevance of CMA alterations and enhances translational prospects. The detailed cellular analyses reveal that the malfunction is not an incidental side effect but a targeted failure of protein clearance pathways specific to motor neuron populations impacted by ALS.

The scientific team’s multidisciplinary collaboration included experts from the UMH Sports Research Centre and the Pascual Parrilla Murcia Institute for Biosanitary Research, reflecting the integrated efforts required to tackle a disease of such complexity. They point out that this work was only feasible thanks to the invaluable donations of neural tissue by ALS patients and their families. Such altruistic contributions provide irreplaceable biological material essential for unraveling ALS mechanisms and testing novel hypotheses.

Mechanistically, chaperone-mediated autophagy involves the recognition of substrate proteins by cytosolic chaperones, which then transport these targets to lysosomal membranes bearing LAMP2A receptors. Following binding, substrates translocate into the lysosome for degradation, thus preventing toxic protein build-up. The discovery that LAMP2A expression is diminished in ALS motor neurons suggests that this critical gateway is impaired, obstructing the selective removal of pathological proteins like TDP-43 and potentially amplifying neurotoxicity.

This study’s findings pave the way for exploring CMA-enhancing therapies that could restore cellular balance in ALS-affected neurons. By developing small-molecule activators or gene therapies aimed at increasing LAMP2A levels or stabilizing chaperone function, researchers aim to reverse toxic protein accumulation. Although in the early stages, such strategies could transform the current landscape of ALS treatment, which remains largely supportive without disease-modifying options.

The researchers also underscore the necessity of further investigations to elucidate how CMA dysfunction interacts with other cellular degradation pathways and contributes to the complex ALS pathology. Synergistic therapeutic strategies combining CMA enhancement with modulation of other proteostatic mechanisms may hold the key to achieving meaningful clinical benefits. This integrative view deepens understanding of motor neuron biology under stress and neurodegenerative demands.

Funding for this pivotal work came from several prestigious sources, including the Spanish State Research Agency’s Severo Ochoa Excellence Programme, the Ministry of Science, Innovation and Universities, the Generalitat Valenciana’s Prometeo Programme, and the Instituto de Salud Carlos III’s Advanced Therapies Network (TERAV). Additionally, support from the Next Generation EU initiative and UMH’s Gregoria Ramos Gil Chair on ALS was instrumental in facilitating comprehensive research efforts.

In conclusion, this landmark study reveals that chaperone-mediated autophagy is critically impaired in spinal motor neurons affected by ALS, contributing to the accumulation of neurotoxic TDP-43 aggregates. This deficiency emerges as a compelling molecular target to develop therapeutic approaches capable of preserving motor neuron integrity and delaying disease progression. As scientists decode the complex interplay of cellular clearance systems, new hope arises for patients facing the relentless challenges of ALS.

Subject of Research: Human tissue samples
Article Title: Chaperone mediated autophagy is deficient in spinal motoneurons of ALS patients with TDP-43 proteinopathy
News Publication Date: 4-Feb-2026
Web References: http://dx.doi.org/10.1186/s40478-026-02238-6
Image Credits: Instituto de Neurociencias UMH CSIC
Keywords: Amyotrophic lateral sclerosis, ALS, motor neurons, TDP-43, chaperone-mediated autophagy, CMA, protein aggregation, neurodegeneration, LAMP2A, autophagy regulation, neurobiology

The investigative team has identified microscopic intercellular channels known as tunneling nanotubes (TNTs), which serve as physical bridges connecting neighboring neurons. Unlike traditional signaling modalities that rely on diffusible chemical messengers, TNTs enable the hand-delivery of proteins and other cellular cargoes, allowing cells to share molecular contents with their neighbors in a precise and regulated manner. While such exchanges can sometimes be beneficial during cellular stress responses, in Huntington’s disease, TNTs become hijacked pathways through which the toxic mutant huntingtin protein spreads, propagating neurodegeneration.

Central to this discovery is the elucidation of how TNTs form and function in diseased neurons. Researchers revealed that the small GTPase-like protein Rhes, already implicated in Huntington’s pathology, forms a critical functional complex with SLC4A7, a bicarbonate transporter traditionally recognized for its role in maintaining intracellular pH homeostasis. This unexpected partnership orchestrates the emergence of tunneling nanotubes, effectively creating cellular highways along which the mutant huntingtin protein travels from one neuron to another.

Through a series of advanced biochemical and imaging techniques, the team demonstrated that the Rhes–SLC4A7 complex localizes at the neuronal plasma membrane, where it initiates intracellular signaling cascades promoting the polymerization of actin filaments—a cytoskeletal rearrangement fundamental to TNT extension. Genetic silencing or pharmacological inhibition of SLC4A7 disrupted TNT formation, significantly curtailing the intercellular trafficking of the mutant huntingtin protein. This mechanistic insight suggests a potential therapeutic target for halting disease progression by interrupting the physical routes of pathogenic spread.

The implications of this research extend into in vivo models, where genetically modified mice deficient in SLC4A7 presented markedly diminished mutant huntingtin propagation within the striatum. The striatum, a brain region critically affected in Huntington’s disease, revealed a pronounced decrease in neurotoxic transmission, reinforcing the vital role this newly characterized pathway plays in disease dynamics. Inhibiting nanotube-mediated protein transfer may therefore provide a tangible strategy to stem the neuronal damage that underlies clinical symptoms.

Beyond Huntington’s disease, the study carries profound significance for a spectrum of neurodegenerative disorders. Tunneling nanotubes are increasingly recognized as conduits in the intercellular passage of pathological proteins such as tau and alpha-synuclein, hallmark agents in Alzheimer’s and Parkinson’s diseases, respectively. Furthermore, cancer cells leverage similar nanotube structures to exchange survival signals and resist chemotherapeutic agents. By elucidating the Rhes–SLC4A7 axis as a master regulator of TNT biogenesis, this work unveils a molecular linchpin that may be exploited to broadly impede pathological intercellular communication across diverse ailments.

The discovery of SLC4A7’s moonlighting role in TNT formation challenges the traditional view of this protein solely as a pH regulator. It appears that perturbations in intracellular acid-base balance, potentially modulated through SLC4A7 activity, could be intricately tied to cytoskeletal dynamics and membrane remodeling necessary for nanotube extension. This integrative understanding of cellular physiology opens new avenues for drug development aimed at modulating these fundamental processes without compromising essential cell functions.

Senior author Dr. Srinivasa Subramaniam emphasized that these findings revolutionize the conceptual framework of neurodegenerative disease progression. By revealing the machinery that physically mobilizes toxic proteins between neurons, therapeutic strategies can now shift toward targeting the structural origins of pathology transmission, rather than merely attempting to degrade or neutralize the toxic proteins post hoc. Such approaches promise to delay or prevent the cascade of neuronal loss that underpins disability.

Complementing this perspective, Dr. Randy Blakely, director of FAU’s Stiles-Nicholson Brain Institute, highlighted the beacon of hope this research kindles for neurotherapeutics. He noted that targeting cellular “communication tunnels” represents a wholly novel and promising treatment modality that could extend far beyond Huntington’s to encompass other debilitating diseases. This mechanistic insight fortifies the foundational knowledge required to pioneer next-generation medicines capable of halting or even reversing neuropathological spread.

The technical rigor of the study was bolstered by multidisciplinary collaboration, incorporating computational simulations to map protein-protein interactions and dynamic imaging to visualize nanotube formation in real time. Such integrative methodologies underscored the power of combining molecular biology and biophysical analyses to decode complex cellular phenomena. The approach exemplifies how modern science transcends traditional boundaries to yield transformative biomedical discoveries.

As investigations proceed, researchers aim to elucidate the precise biochemical signals downstream of the Rhes–SLC4A7 interaction that drive cytoskeletal rearrangements, and to identify small-molecule inhibitors or biological agents capable of selectively disrupting TNT formation in vulnerable neurons. These endeavors hold the promise of translating foundational research into tangible clinical interventions that can mitigate suffering and improve quality of life for individuals grappling with Huntington’s and related illnesses.

Ultimately, this seminal research reshapes our understanding of neuronal communication in health and disease, revealing that the spread of toxic proteins is an active, mediated process reliant on specialized cellular structures rather than passive diffusion alone. By unmasking the molecular architecture underlying this intercellular highway, scientists have taken a monumental step towards dismantling the pathological networks that propagate neurodegeneration, ushering in a new frontier of hope for millions worldwide.

Subject of Research: Animals

Article Title: Membrane-Associated Rhes–Slc4a7 Complex Orchestrates Tunneling Nanotube Formation and Mutant Huntingtin Spread

News Publication Date: 20-Mar-2026

Image Credits: Emaad Mirza, Florida Atlantic University

Keywords: Huntington’s disease, neurodegenerative diseases, neurons, molecular mapping, nanotubes, protein functions, protein activity, disease progression, disease intervention, signaling pathways, cells, brain, disease control